{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T08:45:00Z","timestamp":1792658700720,"version":"4.5.0"},"reference-count":170,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T00:00:00Z","timestamp":1597363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Mol. Neurosci."],"DOI":"10.3389\/fnmol.2020.00156","type":"journal-article","created":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T16:43:47Z","timestamp":1597423427000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":35,"title":["Pathomechanisms and Clinical Implications of Myasthenic Syndromes Exacerbated and Induced by Medical Treatments"],"prefix":"10.3389","volume":"13","author":[{"given":"Martin","family":"Krenn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Grisold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Wohlfarth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Rath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakan","family":"Cetin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inga","family":"Koneczny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fritz","family":"Zimprich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,8,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1001\/archneur.1975.00490520054008","article-title":"Myasthenia gravis and acetylcholine receptor. Effect of steroids in clinical course and cellular immune response to acetylcholine receptor.","volume":"32","author":"Abramsky","year":"1975","journal-title":"Arch. Neurol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1097\/00000441-199504000-00001","article-title":"D-penicillamine-induced myasthenia gravis: diagnosis obscured by coexisting chronic obstructive pulmonary disease.","volume":"309","author":"Adelman","year":"1995","journal-title":"Am. J. Med. Sci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1212\/wnl.31.12.1562","article-title":"Neuromuscular transmission in rheumatoid arthritis, with and without penicillamine treatment.","volume":"31","author":"Albers","year":"1981","journal-title":"Neurology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1002\/mus.880020305","article-title":"Effects of D-penicillamine on neuromuscular transmission in rats.","volume":"2","author":"Aldrich","year":"1979","journal-title":"Muscle Nerve"},{"key":"B5","doi-asserted-by":"publisher","first-page":"367","DOI":"10.7326\/0003-4819-73-3-367","article-title":"Hypermagnesemia after renal homotransplantation.","volume":"73","author":"Alfrey","year":"1970","journal-title":"Ann. Intern. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1007\/bf02242998","article-title":"D-penicillamine induced myasthenia gravis in rheumatoid arthritis: an unpredictable common occurrence?","volume":"13","author":"Andonopoulos","year":"1994","journal-title":"Clin. Rheumatol."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/bf02230893","article-title":"Myasthenic crisis during intravenous iodinated contrast medium injection.","volume":"7","author":"Anzola","year":"1986","journal-title":"Ital. J. Neurol. Sci."},{"key":"B8","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1001\/archneur.1986.00520030045010","article-title":"Ampicillin may aggravate clinical and experimental myasthenia gravis.","volume":"43","author":"Argov","year":"1986","journal-title":"Arch. Neurol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1007\/bf00874123","article-title":"Probable exacerbation of myasthenia gravis by ofloxacin.","volume":"240","author":"Azevedo","year":"1993","journal-title":"J. Neurol."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000003782","article-title":"Myasthenia crisis induced by pegylated-interferon in patient with chronic hepatitis c: a case report.","volume":"95","author":"Baik","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1016\/j.bbmt.2019.05.024","article-title":"Noninfectious neurologic complications after allogeneic hematopoietic stem cell transplantation.","volume":"25","author":"Balaguer-Rosello","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"B12","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1212\/wnl.45.2.382","article-title":"Myasthenia gravis during interferon alfa therapy.","volume":"45","author":"Batocchi","year":"1995","journal-title":"Neurology"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1212\/wnl.32.10.1077","article-title":"Penicillamine-induced myasthenia gravis: effects of penicillamine on acetylcholine receptor.","volume":"32","author":"Bever","year":"1982","journal-title":"Neurology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1212\/wnl.49.6.1747-a","article-title":"Onset of myasthenia gravis in a patient with multiple sclerosis during interferon-1b treatment.","volume":"49","author":"Blake","year":"1997","journal-title":"Neurology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/j.1399-6576.2011.02558.x","article-title":"Anesthesia and myasthenia gravis.","volume":"56","author":"Blichfeldt-Lauridsen","year":"2012","journal-title":"Acta Anaesthesiol. Scand."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1212\/wnl.36.8.1087","article-title":"Myasthenia gravis after allogeneic bone marrow transplantation: relationship to chronic graft-versus-host disease.","volume":"36","author":"Bolger","year":"1986","journal-title":"Neurology"},{"key":"B17","article-title":"Myasthenic crisis following the injection of an iodinated contrast medium.","volume":"13","author":"Bonmarchand","year":"1987","journal-title":"Intensive Care Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1213\/00000539-197805000-00007","article-title":"Neostigmine and 4-aminopyridine antagonism of lincomycin-pancuronium neuromuscular blockade in man.","volume":"57","author":"Booij","year":"1978","journal-title":"Anesth. Analg."},{"key":"B19","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1089\/10799900152434321","article-title":"Myasthenia gravis during low-dose IFN-alpha therapy for chronic hepatitis C.","volume":"21","author":"Borgia","year":"2001","journal-title":"J. Interferon Cytokine Res."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(95)92084-6","article-title":"Myasthenia gravis and levonorgestrel implant.","volume":"346","author":"Brittain","year":"1995","journal-title":"Lancet"},{"key":"B21","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1017\/s0317167100019697","article-title":"Myasthenia gravis associated with diphenylhydantoin therapy for epilepsy.","volume":"1","author":"Brumlik","year":"1974","journal-title":"Can. J. Neurol. Sci."},{"key":"B22","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/jns.12371","article-title":"Incidence and characteristics of neurotoxicity in immune checkpoint inhibitors with focus on neuromuscular events: experience beyond the clinical trials.","volume":"25","author":"Bruna","year":"2020","journal-title":"J. Peripher. Nerv. Syst."},{"key":"B23","first-page":"308","article-title":"[Exacerbation of pseudoparalytic myasthenia gravis following azithromycin (Zithromax)].","volume":"126","author":"Cadisch","year":"1996","journal-title":"Schweiz Med. Wochenschr"},{"key":"B24","first-page":"369","article-title":"The neuromuscular blocking effects of therapeutic concentrations of various antibiotics on normal rat skeletal muscle: a quantitative comparison.","volume":"217","author":"Caputy","year":"1981","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1212\/01.wnl.0000145708.03876.c3","article-title":"Statin-associated exacerbation of myasthenia gravis.","volume":"63","author":"Cartwright","year":"2004","journal-title":"Neurology"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1053\/j.jvca.2018.07.036","article-title":"Myasthenia gravis and thymoma surgery: a clinical update for the cardiothoracic anesthesiologist.","volume":"33","author":"Cata","year":"2019","journal-title":"J. Cardiothorac. Vasc. Anesth."},{"key":"B27","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1055\/s-0038-1660500","article-title":"Pathogenic mechanisms and clinical correlations in autoimmune myasthenic syndromes.","volume":"38","author":"Cetin","year":"2018","journal-title":"Semin. Neurol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1212\/wnl.35.8.1219","article-title":"Myasthenic crisis after intravenous administration of iodinated contrast agent.","volume":"35","author":"Chagnac","year":"1985","journal-title":"Neurology"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.4110\/in.2020.20.e9","article-title":"Clinical characteristics and treatment of immune-related adverse events of immune checkpoint inhibitors.","volume":"20","author":"Choi","year":"2020","journal-title":"Immune Netw."},{"key":"B30","doi-asserted-by":"publisher","first-page":"231","DOI":"10.3233\/JND-170293","article-title":"Beta-2 adrenergic receptor agonists enhance AChR clustering in C2C12 myotubes: implications for therapy of myasthenic disorders.","volume":"5","author":"Clausen","year":"2018","journal-title":"J. Neuromuscul. Dis."},{"key":"B31","first-page":"35S","article-title":"Myasthenia gravis and preeclampsia.","volume":"48","author":"Cohen","year":"1976","journal-title":"Obstet. Gynecol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1159\/000117380","article-title":"Fulminant myasthenia gravis soon after initiation of acebutolol therapy.","volume":"30","author":"Confavreux","year":"1990","journal-title":"Eur. Neurol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1097\/CND.0b013e318285257f","article-title":"Pegylated interferon induced myasthenia crisis\u2013a case report.","volume":"14","author":"Congeni","year":"2013","journal-title":"J. Clin. Neuromuscul. Dis."},{"key":"B34","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1002\/1097-0142(19900515)65:10<2237::aid-cncr2820651013<3.0.co;2-5","article-title":"Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy.","volume":"65","author":"Conlon","year":"1990","journal-title":"Cancer"},{"key":"B35","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/0002-9394(87)90366-7","article-title":"Timolol-associated myasthenia gravis.","volume":"98","author":"Coppeto","year":"1984","journal-title":"Am. J. Ophthalmol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1055\/s-0035-1571213","article-title":"Botulinum toxin: preparations for clinical use, immunogenicity, side effects, and safety profile.","volume":"36","author":"Dashtipour","year":"2016","journal-title":"Semin. Neurol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"371","DOI":"10.2174\/0929867013373435","article-title":"Adverse reactions to fluoroquinolones. an overview on mechanistic aspects.","volume":"8","author":"De Sarro","year":"2001","journal-title":"Curr. Med. Chem."},{"key":"B38","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1113\/jphysiol.1954.sp005114","article-title":"The nature of the neuromuscular block produced by magnesium.","volume":"124","author":"del Castillo","year":"1954","journal-title":"J. Physiol. (Lond.)"},{"key":"B39","doi-asserted-by":"publisher","first-page":"5050","DOI":"10.4049\/jimmunol.175.8.5050","article-title":"Estrogen enhances susceptibility to experimental autoimmune myasthenia gravis by promoting type 1-polarized immune responses.","volume":"175","author":"Delpy","year":"2005","journal-title":"J. Immunol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/bf00582150","article-title":"Corticosteroids and neuromuscular transmission: electrophysiological investigation of the effects of prednisolone on normal and anticholinesterase-treated neuromuscular junction.","volume":"380","author":"Dengler","year":"1979","journal-title":"Pflugers Arch."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1136\/jnnp.2003.028233","article-title":"Development of myasthenia gravis in two patients with multiple sclerosis following interferon beta treatment.","volume":"75","author":"Dionisiotis","year":"2004","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1468-1331.2006.01648.x","article-title":"The structure and mode of action of different botulinum toxins.","volume":"13","author":"Dolly","year":"2006","journal-title":"Eur. J. Neurol."},{"key":"B43","first-page":"387","article-title":"D-penicillamine induced myasthenia gravis: clinical, serological and genetic findings.","volume":"11","author":"Drosos","year":"1993","journal-title":"Clin. Exp. Rheumatol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/j.1476-5381.1981.tb09102.x","article-title":"The action of polymyxin B at the frog neuromuscular junction.","volume":"72","author":"Durant","year":"1981","journal-title":"Br. J. Pharmacol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1212\/wnl.40.10.1623","article-title":"Aggravation of human and experimental myasthenia gravis by contrast media.","volume":"40","author":"Eliashiv","year":"1990","journal-title":"Neurology"},{"key":"B46","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1113\/jphysiol.1964.sp007495","article-title":"An electrophysiological investigation of neuromuscular transmission in myasthenia gravis.","volume":"174","author":"Elmqvist","year":"1964","journal-title":"J. Physiol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1136\/jnnp.56.11.1235","article-title":"Systemic effect of local botulinum toxin injections unmasks subclinical Lambert-Eaton myasthenic syndrome.","volume":"56","author":"Erbguth","year":"1993","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"B48","doi-asserted-by":"publisher","first-page":"649","DOI":"10.2165\/00002018-200225090-00004","article-title":"Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same?","volume":"25","author":"Evans","year":"2002","journal-title":"Drug Saf."},{"key":"B49","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1111\/j.1600-065X.2008.00662.x","article-title":"Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways.","volume":"224","author":"Fife","year":"2008","journal-title":"Immunol. Rev."},{"key":"B50","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1001\/archneur.1965.00460300010002","article-title":"Neurological aspects of magnesium metabolism.","volume":"12","author":"Fishman","year":"1965","journal-title":"Arch. Neurol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1212\/wnl.37.8.1400","article-title":"Iodinated contrast agents in myasthenia gravis.","volume":"37","author":"Frank","year":"1987","journal-title":"Neurology"},{"key":"B52","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1111\/j.1476-5381.1976.tb07476.x","article-title":"Effects of several inhalation anaesthetics on the kinetics of postsynaptic conductance changes in mouse diaphragm.","volume":"57","author":"Gage","year":"1976","journal-title":"Br. J. Pharmacol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.jocn.2013.11.009","article-title":"Statins can induce myasthenia gravis.","volume":"21","author":"Gale","year":"2014","journal-title":"J. Clin. Neurosci."},{"key":"B54","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/mds.870080106","article-title":"Time course of distant effects of local injections of botulinum toxin.","volume":"8","author":"Garner","year":"1993","journal-title":"Mov. Disord."},{"key":"B55","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1097\/00007691-199007000-00019","article-title":"Procainamide-induced myasthenic crisis.","volume":"12","author":"Godley","year":"1990","journal-title":"Ther. Drug Monit."},{"key":"B56","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1084\/jem.181.2.547","article-title":"Myasthenia gravis-like syndrome induced by expression of interferon gamma in the neuromuscular junction.","volume":"181","author":"Gu","year":"1995","journal-title":"J. Exp. Med."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1212\/CON.0000000000000807","article-title":"Lambert-eaton myasthenic syndrome, botulism, and immune checkpoint inhibitor-related myasthenia gravis.","volume":"25","author":"Guidon","year":"2019","journal-title":"Continuum (Minneap Minn)"},{"key":"B58","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1002\/mus.26689","article-title":"Factors associated with acute exacerbations of myasthenia gravis.","volume":"60","author":"Gummi","year":"2019","journal-title":"Muscle Nerve"},{"key":"B59","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1136\/emj.2006.038091","article-title":"Levofloxacin induced myasthenia crisis.","volume":"23","author":"Gunduz","year":"2006","journal-title":"Emerg. Med. J."},{"key":"B60","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1212\/wnl.23.9.977","article-title":"Effect of Mg++ on neuromuscular transmission in the Eaton-Lambert syndrome.","volume":"23","author":"Gutmann","year":"1973","journal-title":"Neurology"},{"key":"B61","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/j.1476-5381.1974.tb09710.x","article-title":"The effects of three beta-adrenoceptor blocking drugs on isolated preparations of skeletal and cardiac muscle.","volume":"52","author":"Harry","year":"1974","journal-title":"Br. J. Pharmacol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14740338.2020.1738382","article-title":"Neurologic complications of immune checkpoint inhibitors.","volume":"18","author":"Haugh","year":"2020","journal-title":"Expert Opin. Drug Saf."},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000645","article-title":"SHP2 inhibitor protects AChRs from effects of myasthenia gravis MuSK antibody.","volume":"7","author":"Huda","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"B64","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.tripleo.2009.01.015","article-title":"Perioperative management of patients with myasthenia gravis: prevention, recognition, and treatment.","volume":"107","author":"Jamal","year":"2009","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1086\/509646","article-title":"Telithromycin and myasthenic crisis.","volume":"43","author":"Jennett","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"B66","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1212\/WNL.0000000000007235","article-title":"Neuromuscular adverse events associated with anti-PD-1 monoclonal antibodies: systematic review.","volume":"92","author":"Johansen","year":"2019","journal-title":"Neurology"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0617-x","article-title":"Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study.","volume":"7","author":"Johnson","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"B68","doi-asserted-by":"publisher","first-page":"e122","DOI":"10.1200\/JCO.2013.51.1683","article-title":"Myasthenia gravis induced by ipilimumab in patients with metastatic melanoma.","volume":"33","author":"Johnson","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1002\/(SICI)1097-4598(199608)19:8<959::AID-MUS4<3.0.CO;2-7","article-title":"Acute effects of intravenous injection of beta-adrenoreceptor- and calcium channel at antagonists and agonists in myasthenia gravis.","volume":"19","author":"Jonkers","year":"1996","journal-title":"Muscle Nerve"},{"key":"B70","first-page":"39","article-title":"Drug-induced myasthenic syndromes.","volume":"100","author":"Kaeser","year":"1984","journal-title":"Acta Neurol. Scand. Suppl."},{"key":"B71","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jns.2018.10.018","article-title":"Predictive score for oral corticosteroid-induced initial worsening of seropositive generalized myasthenia gravis.","volume":"396","author":"Kanai","year":"2019","journal-title":"J. Neurol. Sci."},{"key":"B72","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1002\/mus.25155","article-title":"Statins and myasthenia gravis.","volume":"54","author":"Khalid","year":"2016","journal-title":"Muscle Nerve"},{"key":"B73","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1002\/mus.880200501","article-title":"Unmasking and exacerbation of myasthenia gravis by ophthalmic solutions: betoxolol, tobramycin, and dexamethasone. A case report.","volume":"20","author":"Khella","year":"1997","journal-title":"Muscle Nerve"},{"key":"B74","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/0022-510x(79)90041-8","article-title":"Short-term effects of prednisolone on neuromuscular transmission in normal rats and those with experimental autoimmune myasthenia gravis.","volume":"41","author":"Kim","year":"1979","journal-title":"J. Neurol. Sci."},{"key":"B75","doi-asserted-by":"publisher","first-page":"3583","DOI":"10.1111\/cas.13800","article-title":"Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab.","volume":"109","author":"Kimbara","year":"2018","journal-title":"Cancer Sci."},{"key":"B76","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1212\/01.wnl.0000137021.90567.37","article-title":"Effect of D-penicillamine on neuromuscular junction in patients with Wilson disease.","volume":"63","author":"Komal Kumar","year":"2004","journal-title":"Neurology"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3390\/cells8070671","article-title":"Myasthenia gravis: pathogenic effects of autoantibodies on neuromuscular architecture.","volume":"8","author":"Koneczny","year":"2019","journal-title":"Cells"},{"key":"B78","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1055\/s-2008-1041252","article-title":"Hypermagnesemia and neuromuscular transmission.","volume":"10","author":"Krendel","year":"1990","journal-title":"Semin. Neurol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/mus.880090607","article-title":"Adverse effect of verapamil in a patient with the Lambert-Eaton syndrome.","volume":"9","author":"Krendel","year":"1986","journal-title":"Muscle Nerve"},{"key":"B80","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1002\/ana.410200617","article-title":"The pathophysiology of penicillamine-induced myasthenia gravis.","volume":"20","author":"Kuncl","year":"1986","journal-title":"Ann. Neurol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1002\/mus.880060608","article-title":"Presynaptic and postsynaptic actions of procainamide on neuromuscular transmission.","volume":"6","author":"Lee","year":"1983","journal-title":"Muscle Nerve"},{"key":"B82","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/nyas.13538","article-title":"Therapeutic strategies for congenital myasthenic syndromes.","volume":"1412","author":"Lee","year":"2018","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"B83","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1056\/NEJM198707163170315","article-title":"Antibodies against the acetylcholine receptor in hematologic disorders: implications for the development of myasthenia gravis after bone marrow grafting.","volume":"317","author":"Lefvert","year":"1987","journal-title":"N. Engl. J. Med."},{"key":"B84","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1046\/j.1468-1331.2000.00042.x","article-title":"Effects of sex hormones on experimental autoimmune myasthenia gravis.","volume":"7","author":"Leker","year":"2000","journal-title":"Eur. J. Neurol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1080\/22953337.1987.11719269","article-title":"Possible revelation of latent myasthenia gravis by labetalol chlorhydrate.","volume":"42","author":"Leys","year":"1987","journal-title":"Acta Clin. Belg."},{"key":"B86","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1542\/peds.47.3.501","article-title":"The clinical and biochemical effects of excess magnesium in the newborn.","volume":"47","author":"Lipsitz","year":"1971","journal-title":"Pediatrics"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-198702000-00030","article-title":"Myasthenia gravis unmasked by lithium carbonate.","volume":"7","author":"Lipton","year":"1987","journal-title":"J. Clin. Psychopharmacol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.toxlet.2010.02.005","article-title":"Telithromycin blocks neuromuscular transmission and inhibits nAChR currents in vitro.","volume":"194","author":"Liu","year":"2010","journal-title":"Toxicol. Lett."},{"key":"B89","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/s0140-6736(54)91566-4","article-title":"See-saw relationship between hyperthyroidism and myasthenia gravis.","volume":"266","author":"Maclean","year":"1954","journal-title":"Lancet"},{"key":"B90","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.bbmt.2016.12.632","article-title":"Neurologic complications after allogeneic hematopoietic stem cell transplantation.","volume":"23","author":"Maffini","year":"2017","journal-title":"Biol. Blood Marrow Transplant."},{"key":"B91","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/0896-6273(93)90270-2","article-title":"Interaction of the 43 kd postsynaptic protein with all subunits of the muscle nicotinic acetylcholine receptor.","volume":"11","author":"Maimone","year":"1993","journal-title":"Neuron"},{"key":"B92","doi-asserted-by":"publisher","first-page":"136","DOI":"10.4103\/jnrp.jnrp_150_18","article-title":"See-saw relationship and its reversal after immunotherapy in a case of Graves\u2019 disease with coexisting myasthenia gravis.","volume":"10","author":"Mallikarjuna","year":"2019","journal-title":"J. Neurosci. Rural Pract."},{"key":"B93","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1002\/ana.410280417","article-title":"Aggravation of myasthenia gravis by erythromycin.","volume":"28","author":"May","year":"1990","journal-title":"Ann. Neurol."},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31180-6","article-title":"Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis.","volume":"395","author":"Mehra","year":"2020","journal-title":"Lancet"},{"key":"B95","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1002\/mus.24254","article-title":"Complications of radiologic contrast in patients with myasthenia gravis.","volume":"50","author":"Mehrizi","year":"2014","journal-title":"Muscle Nerve"},{"key":"B96","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review.","volume":"54","author":"Michot","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"B97","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1196\/annals.1254.032","article-title":"T cells and cytokines in the pathogenesis of acquired myasthenia gravis.","volume":"998","author":"Milani","year":"2003","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"B98","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1097\/00007691-199306000-00013","article-title":"Procainamide-induced myasthenia-like weakness and dysphagia.","volume":"15","author":"Miller","year":"1993","journal-title":"Ther. Drug Monit."},{"key":"B99","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.2169\/internalmedicine.9153-17","article-title":"Relapsed myasthenia gravis after nivolumab treatment.","volume":"57","author":"Mitsune","year":"2018","journal-title":"Intern. Med."},{"key":"B100","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/bf00915071","article-title":"Carbamycholine modulation of E-rosette formation: identification of nicotinic acetylcholine receptors on a subpopulation of human T lymphocytes.","volume":"2","author":"Mizuno","year":"1982","journal-title":"J. Clin. Immunol."},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2018.00150","article-title":"Myasthenia gravis induced by Ipilimumab in a patient with metastatic melanoma.","volume":"9","author":"Montes","year":"2018","journal-title":"Front. Neurol."},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(88)91627-3","article-title":"Possible exacerbation of myasthenia gravis by ciprofloxacin.","volume":"1","author":"Moore","year":"1988","journal-title":"Lancet"},{"key":"B103","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1136\/bmj.301.6755.818-a","article-title":"Ciprofloxacin and myasthenia gravis.","volume":"301","author":"Mumford","year":"1990","journal-title":"BMJ"},{"key":"B104","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1001\/archpsyc.1976.01770090080007","article-title":"Emergence of myasthenia gravis during treatment with lithium carbonate.","volume":"33","author":"Neil","year":"1976","journal-title":"Arch. Gen. Psychiatry"},{"key":"B105","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1086\/379617","article-title":"Telithromycin and myasthenia gravis.","volume":"37","author":"Nieman","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"B106","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1097\/00000542-199007000-00005","article-title":"Vecuronium dose-response and maintenance requirements in patients with myasthenia gravis.","volume":"73","author":"Nilsson","year":"1990","journal-title":"Anesthesiology"},{"key":"B107","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1093\/bja\/ael368","article-title":"Neuromuscular effects of sevoflurane in myasthenia gravis patients.","volume":"98","author":"Nitahara","year":"2007","journal-title":"Br. J. Anaesth."},{"key":"B108","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1212\/wnl.14.9.869","article-title":"Effect of diphenylhydantoin on neuromuscular synapse.","volume":"14","author":"Norris","year":"1964","journal-title":"Neurology"},{"key":"B109","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1002\/mus.21074","article-title":"Statins may aggravate myasthenia gravis.","volume":"38","author":"Oh","year":"2008","journal-title":"Muscle Nerve"},{"key":"B110","first-page":"670","article-title":"Procainamide-induced myasthenia-like syndrome.","volume":"9","author":"Oh","year":"1986","journal-title":"Muscle Nerve"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)09846-X","article-title":"Statins, fibrates, and ocular myasthenia.","volume":"360","author":"Parmar","year":"2002","journal-title":"Lancet"},{"key":"B112","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/ana.410150316","article-title":"Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients.","volume":"15","author":"Pascuzzi","year":"1984","journal-title":"Ann. Neurol."},{"key":"B113","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.mayocp.2012.01.012","article-title":"Clinical pharmacology, uses, and adverse reactions of iodinated contrast agents: a primer for the non-radiologist.","volume":"87","author":"Pasternak","year":"2012","journal-title":"Mayo Clin. Proc."},{"key":"B114","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1111\/j.1749-6632.1998.tb10961.x","article-title":"Drug-induced autoimmune myasthenia gravis.","volume":"841","author":"Penn","year":"1998","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"B115","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1212\/01.wnl.0000247741.72466.8c","article-title":"Myasthenia gravis exacerbation or unmasking associated with telithromycin treatment.","volume":"67","author":"Perrot","year":"2006","journal-title":"Neurology"},{"key":"B116","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/0006-8993(87)91137-1","article-title":"Mechanism of action of lithium on acetylcholine receptor metabolism in skeletal muscle.","volume":"412","author":"Pestronk","year":"1987","journal-title":"Brain Res."},{"key":"B117","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.nmd.2013.04.001","article-title":"Quinine sulfate as a therapeutic option in a patient with slow channel congenital myasthenic syndrome.","volume":"23","author":"Peyer","year":"2013","journal-title":"Neuromuscul. Disord."},{"key":"B118","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1146\/annurev.pa.12.040172.001125","article-title":"Antibiotic blockade of neuromuscular function.","volume":"12","author":"Pittinger","year":"1972","journal-title":"Annu. Rev. Pharmacol."},{"key":"B119","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune checkpoint blockade in cancer therapy.","volume":"33","author":"Postow","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"B120","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade.","volume":"378","author":"Postow","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B121","first-page":"107","article-title":"The use of magnesium sulfate in preeclampsia-eclampsia.","volume":"23","author":"Pritchard","year":"1979","journal-title":"J. Reprod. Med."},{"key":"B122","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1212\/wnl.46.5.1391","article-title":"Calcium channel blockers and transmitter release at the normal human neuromuscular junction.","volume":"46","author":"Protti","year":"1996","journal-title":"Neurology"},{"key":"B123","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1097\/01.md.0000209337.59874.aa","article-title":"Statin-associated myasthenia gravis: report of 4 cases and review of the literature.","volume":"85","author":"Purvin","year":"2006","journal-title":"Medicine (Baltimore)"},{"key":"B124","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1007\/s00415-017-8518-8","article-title":"Iodinated contrast agents in patients with myasthenia gravis: a retrospective cohort study.","volume":"264","author":"Rath","year":"2017","journal-title":"J. Neurol."},{"key":"B125","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/0742-8413(89)90023-6","article-title":"The actions of verapamil at the neuromuscular junction.","volume":"93","author":"Ribera","year":"1989","journal-title":"Comp. Biochem. Physiol. C Comp. Pharmacol. Toxicol."},{"key":"B126","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/archneur.1989.00520400124033","article-title":"Myasthenic syndrome caused by direct effect of chloroquine on neuromuscular junction.","volume":"46","author":"Robberecht","year":"1989","journal-title":"Arch. Neurol."},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.2214\/ajr.162.4.8141034","article-title":"Exacerbation of myasthenia gravis by contrast media.","volume":"162","author":"Rocha","year":"1994","journal-title":"AJR Am. J. Roentgenol."},{"key":"B128","first-page":"1043","article-title":"[Myasthenic syndrome induced by lithium].","volume":"29","author":"Ronzi\u00e8re","year":"2000","journal-title":"Presse Med."},{"key":"B129","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1111\/j.1600-0404.1996.tb00055.x","article-title":"Myasthenia gravis and ciprofloxacin.","volume":"94","author":"Roquer","year":"1996","journal-title":"Acta Neurol. Scand."},{"key":"B130","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1213\/00000539-197705000-00001","article-title":"Comparative neuromuscular effects of lincomycin and clindamycin.","volume":"56","author":"Rubbo","year":"1977","journal-title":"Anesth. Analg."},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0774-y","article-title":"Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature.","volume":"7","author":"Safa","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"B132","first-page":"618","article-title":"Unmasking of myasthenia gravis during pegylated Alfa 2 a interferon and ribavirin therapy for chronic hepatitis C.","volume":"66","author":"Saleem","year":"2016","journal-title":"J. Pak. Med. Assoc."},{"key":"B133","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11060-019-03273-1","article-title":"Neurological and related adverse events in immune checkpoint inhibitors: a pharmacovigilance study from the Japanese adverse drug event report database.","volume":"145","author":"Sato","year":"2019","journal-title":"J. Neurooncol."},{"key":"B134","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1080\/17425255.2016.1215426","article-title":"Clinical pharmacology and efficacy of sugammadex in the reversal of neuromuscular blockade.","volume":"12","author":"Schaller","year":"2016","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"B135","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1056\/NEJM197401102900204","article-title":"Gradually increasing doses of prednisone in myasthenia gravis. Reducing the hazards of treatment.","volume":"290","author":"Seybold","year":"1974","journal-title":"N. Engl. J. Med."},{"key":"B136","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/1759-7714.13266","article-title":"Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor-related adverse reactions in the nervous system.","volume":"11","author":"Shi","year":"2020","journal-title":"Thorac. Cancer"},{"key":"B137","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/0006-8993(95)01349-0","article-title":"Effects of the quinoline derivatives quinine, quinidine, and chloroquine on neuromuscular transmission.","volume":"712","author":"Sieb","year":"1996","journal-title":"Brain Res."},{"key":"B138","doi-asserted-by":"publisher","first-page":"495","DOI":"10.14503\/THIJ-14-4584","article-title":"Acute respiratory failure induced by magnesium replacement in a 62-year-old woman with myasthenia gravis.","volume":"42","author":"Singh","year":"2015","journal-title":"Tex Heart Inst. J."},{"key":"B139","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1097\/00000542-197806000-00008","article-title":"Antibiotic-induced paralysis of the mouse phrenic nerve-hemidiaphragm preparation, and reversibility by calcium and by neostigmine.","volume":"48","author":"Singh","year":"","journal-title":"Anesthesiology"},{"key":"B140","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/j.2042-7158.1978.tb13216.x","article-title":"Reversal of antibiotic-induced muscle paralysis by 3,4-diaminopyridine.","volume":"30","author":"Singh","year":"","journal-title":"J. Pharm. Pharmacol."},{"key":"B141","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0072-9752(07)01502-3","article-title":"Reliability of neuromuscular transmission and how it is maintained.","volume":"91","author":"Slater","year":"2008","journal-title":"Handb. Clin. Neurol."},{"key":"B142","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1148\/radiol.12121508","article-title":"Effect of intravenous low-osmolality iodinated contrast media on patients with myasthenia gravis.","volume":"267","author":"Somashekar","year":"2013","journal-title":"Radiology"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2019.102368","article-title":"Thyroid disorders in patients with myasthenia gravis: a systematic review and meta-analysis.","volume":"18","author":"Song","year":"2019","journal-title":"Autoimmun. Rev."},{"key":"B144","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1002\/mus.880150321","article-title":"Adverse effect of verapamil in myasthenia gravis.","volume":"15","author":"Swash","year":"1992","journal-title":"Muscle Nerve"},{"key":"B145","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/mus.880020409","article-title":"Weakness from magnesium-containing cathartics: electrophysiologic studies.","volume":"2","author":"Swift","year":"1979","journal-title":"Muscle Nerve"},{"key":"B146","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1159\/000502350","article-title":"Cosmetic injection of botulinum toxin unmasking subclinical myasthenia gravis: a case report and literature review.","volume":"11","author":"Timmermans","year":"2019","journal-title":"Case Rep. Neurol."},{"key":"B147","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/S1474-4422(11)70245-9","article-title":"Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies.","volume":"10","author":"Titulaer","year":"2011","journal-title":"Lancet Neurol."},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104762","article-title":"Of chloroquine and COVID-19.","volume":"177","author":"Touret","year":"2020","journal-title":"Antiviral Res."},{"key":"B149","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.hemonc.2017.04.001","article-title":"Myasthenia gravis after allogeneic bone marrow transplantation: a case report and literature review.","volume":"12","author":"Tsutsumi","year":"2019","journal-title":"Hematol. Oncol. Stem Cell Ther."},{"key":"B150","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1007\/s10072-020-04387-5","article-title":"Exacerbation of myasthenia gravis after amoxicillin therapy: a case series.","volume":"41","author":"Vacchiano","year":"2020","journal-title":"Neurol. Sci."},{"key":"B151","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.atherosclerosis.2008.05.021","article-title":"Molecular basis of statin-associated myopathy.","volume":"202","author":"Vaklavas","year":"2009","journal-title":"Atherosclerosis"},{"key":"B152","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1097\/WCO.0000000000000736","article-title":"The congenital myasthenic syndromes: expanding genetic and phenotypic spectrums and refining treatment strategies.","volume":"32","author":"Vanhaesebrouck","year":"2019","journal-title":"Curr. Opin. Neurol."},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.4081\/reumatismo.2015.849","article-title":"Myasthenia gravis due to hydroxychloroquine.","volume":"67","author":"Varan","year":"2015","journal-title":"Reumatismo"},{"key":"B154","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/ana.410170222","article-title":"Worsening of myasthenia gravis with timolol maleate eyedrops.","volume":"17","author":"Verkijk","year":"1985","journal-title":"Ann. Neurol."},{"key":"B155","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1136\/jnnp.40.11.1060","article-title":"Acetylcholinesterase activity and menstrual remissions in myasthenia gravis.","volume":"40","author":"Vijayan","year":"1977","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(78)92481-9","article-title":"Anti-acetylcholine receptor antibodies in D-penicillamine-associated myasthenia gravis.","volume":"1","author":"Vincent","year":"1978","journal-title":"Lancet"},{"key":"B157","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1002\/jps.2600670922","article-title":"Neuromuscular block of the polymyxin group of antibiotics.","volume":"67","author":"Viswanath","year":"1978","journal-title":"J. Pharm. Sci."},{"key":"B158","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1016\/j.jocn.2015.05.032","article-title":"Myasthenia gravis exacerbation with low dose ocular botulinum toxin for epiphoria.","volume":"22","author":"Watts","year":"2015","journal-title":"J. Clin. Neurosci."},{"key":"B159","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1001\/jama.1949.62910130001008","article-title":"Masked myasthenia gravis.","volume":"141","author":"Weisman","year":"1949","journal-title":"J. Am. Med. Assoc."},{"key":"B160","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1212\/wnl.24.11.1091","article-title":"Corticosteroids: a direct effect at the neuromuscular junction.","volume":"24","author":"Wilson","year":"1974","journal-title":"Neurology"},{"key":"B161","first-page":"745","article-title":"Exacerbation of myasthenia gravis during imiquimod treatment.","volume":"6","author":"Wolfe","year":"2007","journal-title":"J. Drugs Dermatol."},{"key":"B162","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1056\/NEJMc1611704","article-title":"Randomized trial of thymectomy in myasthenia gravis.","volume":"375","author":"Wolfe","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B163","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/s0301-0082(00)00055-1","article-title":"Safety factor at the neuromuscular junction.","volume":"64","author":"Wood","year":"2001","journal-title":"Prog. Neurobiol."},{"key":"B164","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1139\/y76-129","article-title":"The site of the neuromuscular block produced by polymyxin B and rolitetracycline.","volume":"54","author":"Wright","year":"1976","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2020.01.79","article-title":"Myositis-myasthenia gravis overlap syndrome complicated with myasthenia crisis and myocarditis associated with anti-programmed cell death-1 (sintilimab) therapy for lung adenocarcinoma.","volume":"8","author":"Xing","year":"2020","journal-title":"Ann. Transl. Med."},{"key":"B166","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1002\/ana.410010405","article-title":"Depression of synaptic transmission by diphenylhydantoin.","volume":"1","author":"Yaari","year":"1977","journal-title":"Ann. Neurol."},{"key":"B167","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3109\/01480549209035172","article-title":"Exacerbated muscle dysfunction by procainamide in rats with experimental myasthenia gravis.","volume":"15","author":"Yeh","year":"1992","journal-title":"Drug Chem. Toxicol."},{"key":"B168","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/nature01158","article-title":"The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease.","volume":"420","author":"Youssef","year":"2002","journal-title":"Nature"},{"key":"B169","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1056\/NEJMra1703472","article-title":"Pathophysiology of chronic graft-versus-host disease and therapeutic targets.","volume":"377","author":"Zeiser","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B170","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1056\/NEJMc1716969","article-title":"Acute graft-versus-host disease.","volume":"378","author":"Zeiser","year":"2018","journal-title":"N. Engl. J. Med."}],"container-title":["Frontiers in Molecular Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fnmol.2020.00156\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T00:02:50Z","timestamp":1667779370000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fnmol.2020.00156\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,14]]},"references-count":170,"alternative-id":["10.3389\/fnmol.2020.00156"],"URL":"https:\/\/doi.org\/10.3389\/fnmol.2020.00156","relation":{},"ISSN":["1662-5099"],"issn-type":[{"value":"1662-5099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,14]]},"article-number":"156"}}